Yilmaz, K.B.; Tavukcuoglu, E.; Yanik, H.; Seçken, P.; Celik, E.; Guler, S.; Hidiroglu, M.M.; Bahcecioglu, I.B.; Erturk, I.; Gulcelik, M.A.;
et al. Alterations in PD-L1+ Myeloid Cells and Immune Infiltration Are Associated with Atezolizumab and Paclitaxel Therapy Success in a Triple-Negative Breast Cancer Model. Medicina 2026, 62, 600.
https://doi.org/10.3390/medicina62030600
AMA Style
Yilmaz KB, Tavukcuoglu E, Yanik H, Seçken P, Celik E, Guler S, Hidiroglu MM, Bahcecioglu IB, Erturk I, Gulcelik MA,
et al. Alterations in PD-L1+ Myeloid Cells and Immune Infiltration Are Associated with Atezolizumab and Paclitaxel Therapy Success in a Triple-Negative Breast Cancer Model. Medicina. 2026; 62(3):600.
https://doi.org/10.3390/medicina62030600
Chicago/Turabian Style
Yilmaz, Kerim Bora, Ece Tavukcuoglu, Hamdullah Yanik, Pelin Seçken, Ertugrul Celik, Sumeyra Guler, Mehmet Mert Hidiroglu, Ibrahim Burak Bahcecioglu, Ismail Erturk, Mehmet Ali Gulcelik,
and et al. 2026. "Alterations in PD-L1+ Myeloid Cells and Immune Infiltration Are Associated with Atezolizumab and Paclitaxel Therapy Success in a Triple-Negative Breast Cancer Model" Medicina 62, no. 3: 600.
https://doi.org/10.3390/medicina62030600
APA Style
Yilmaz, K. B., Tavukcuoglu, E., Yanik, H., Seçken, P., Celik, E., Guler, S., Hidiroglu, M. M., Bahcecioglu, I. B., Erturk, I., Gulcelik, M. A., Karakoc, D., & Esendagli, G.
(2026). Alterations in PD-L1+ Myeloid Cells and Immune Infiltration Are Associated with Atezolizumab and Paclitaxel Therapy Success in a Triple-Negative Breast Cancer Model. Medicina, 62(3), 600.
https://doi.org/10.3390/medicina62030600
